Phase II trial of a Novel Intravitreal Plasma Kallikrein Inhibitor (KVD-001) in Subjects with Diabetic Macular Edema

Trial Profile

Phase II trial of a Novel Intravitreal Plasma Kallikrein Inhibitor (KVD-001) in Subjects with Diabetic Macular Edema

Planning
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2016

At a glance

  • Drugs KVD 001 (Primary)
  • Indications Diabetic macular oedema
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 22 Nov 2016 According to a KalVista Pharmaceuticals media release, this study is expected to start in 2017.
    • 25 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top